Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens

• Robert A. Smith ,

  * E-mail: smithra@u.washington.edu

  Affiliation Department of Pathology, University of Washington, Seattle, Washington, United States of America

  ⨯
• Dana N. Raugi,

  Affiliation Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, United States of America

  ⨯
• Charlotte Pan,

  Affiliation Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, United States of America

  ⨯
• Matthew Coyne,

  Affiliation College of Arts and Sciences, University of Washington, Seattle, Washington, United States of America

  ⨯
• Alexandra Hernandez,

  Affiliation College of Arts and Sciences, University of Washington, Seattle, Washington, United States of America

  ⨯
• Brad Church,

  Affiliation College of Arts and Sciences, University of Washington, Seattle, Washington, United States of America

  ⨯
• Kara Parker,

  Affiliation College of Arts and Sciences, University of Washington, Seattle, Washington, United States of America

  ⨯
• James I. Mullins,

  Affiliation Department of Microbiology, University of Washington, Seattle, Washington, United States of America

  ⨯
• Papa Salif Sow,

  Affiliation Clinique des Maladies Infectieuses Ibrahima DIOP Mar, Centre Hospitalier Universitaire de Fann, Université Cheikh Anta Diop de Dakar, Dakar, Senegal

  ⨯
• Geoffrey S. Gottlieb2 for the University of Washington–Dakar HIV-2 Study Group

  ¶Membership of the University of Washington–Dakar HIV-2 Study Group is provided in the Acknowledgments.

  ⨯